title: [IgIV at home:experience of a center--economic aspects].
abstract: BACKGROUND
  Intravenous Human immunoglobulin (IVIg) administration is a safe and efficacious treatment in IgG deficiency and auto-immune diseases. The most of the patients treated in hospital ask for home treatment.
  
  
  METHODS
  [corrected] Two cost studies were performed: on study comparing the cost of IVIg in hospital and at home in auto-immune diseases and another evaluating the cost of SCIg and IVIg in hospital and at home in immune deficiency.
  
  
  RESULTS
  The Home treatment by the IVIg is possible with a care society and safe. Any serious adverse events is occurred, because of a good selection of the patients. The total cost of IVIg seems to be cheaper at home than the hospital treatment with IVIg and home treatment with SCIg.
  
  
  CONCLUSIONS
  The home IVIg substitution is possible. This alternative can be proposed at the patient with a stable clinical status, according to his hope and the wish of his family. This alternative is interesting for the life quality and the cost.
authors.affiliation: Hôpital Claude-Huriez, Lille, France. ehachulla@chru-lille.fr
authors.forename: E
authors.initials: E
authors.lastname: Hachulla
mesh_terms: D001327:Autoimmune Diseases / Q000188:drug therapy / Q000191:economics; D005602:France; D018718:Home Infusion Therapy / Q000191:economics* / Q000379:methods*; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000191:economics* / Q000627:therapeutic use; D007155:Immunologic Factors / Q000191:economics* / Q000627:therapeutic use; D011788:Quality of Life; D012646:Self Administration
chemical_list: D016756:Immunoglobulins, Intravenous; D007155:Immunologic Factors